VKTXライブシグナル | Getagraph.comで利益を最大化

買う 135 min ago

@ $74.23

発行日: 29 4月 2024 @ 23:26

リターン: 1.39%

前回のシグナル: 4月 26 - 04:47

前回のシグナル: 売る

リターン: 8.26 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:42):
Our systems believe the stock currently is overvalued by 0.46% compare to its pairs and should correct downwards.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders...

Stats
本日の出来高	1.65M
平均出来高	6.50M
時価総額	8.23B
EPS	$-0.250 ( 2024-04-24 )
次の収益日	( $-0.240 ) 2024-07-24
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-81.80
ATR14	$2.94 (3.91%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Mancini Marianna	Buy	31 667	Common Stock, par value $0.00001 per share
2024-03-27	Mancini Marianna	Sell	16 610	Common Stock, par value $0.00001 per share
2024-03-27	Lian Brian	Buy	221 667	Common Stock, par value $0.00001 per share
2024-03-27	Lian Brian	Sell	153 948	Common Stock, par value $0.00001 per share
2024-03-27	Zante Greg	Buy	31 667	Common Stock, par value $0.00001 per share

INSIDER POWER
10.07
Last 100 transactions
Buy: 2 960 710 \| Sell: 2 536 561

相関 (AI algo v.1.1b): Overvalued: -0.46% $74.80 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

ボリューム相関

長: 0.39 (neutral)

短: -0.63 (weak negative)

Signal:(61) Neutral

Viking Therapeutics Inc 相関

10 最も正の相関
CFFE	0.97
ARIZ	0.966
EMLD	0.96
ARTEU	0.96
AIB	0.958
GENQ	0.956
FTII	0.956
GDST	0.955
ACLS	0.955
BRAC	0.954

10 最も負の相関
SMFL	-0.968
NCBS	-0.963
MYSZ	-0.96
PIII	-0.958
CREG	-0.955
BCAB	-0.95
SPCX	-0.949
KTTA	-0.948
TRIT	-0.947
VFF	-0.947

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Viking Therapeutics Inc 相関 - 通貨/商品

0.42
( neutral )

0.58
( weak )

0.00
( neutral )

0.23
( neutral )

0.57
( weak )

-0.43
( neutral )

Viking Therapeutics Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-292 000 (0.00 %)
EPS:	$-0.910

FY	2023
収益:	$0
総利益:	$-292 000 (0.00 %)
EPS:	$-0.910

FY	2022
収益:	$0
総利益:	$-291 000 (0.00 %)
EPS:	$-0.880

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.757

Financial Reports:

No articles found.

Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.